[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-342281-105":59,"doc-detail-342281-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","immunohistochemical-status-predicts-pathologic-complete-response-to-neoadjuvant-therapy-in-her2-overexpressing-breast-cancers","Immunohistochemical Status Predicts Pathologic Complete Response to Neoadjuvant Therapy in HER2-Overexpressing Breast Cancers","","HER2 overexpression (HER2+) defined by immunohistochemistry (IHC) and in situ hybridization (ISH) shows heterogeneous response to neoadjuvant anti-HER2 therapy across IHC3+ versus IHC2+/ISH+ breast cancers, but differences in pathologic complete response (pCR) remain unclear. A cohort of stage I–III HER2+ patients receiving neoadjuvant therapy and surgery (2013–2020) from the National Cancer Database was stratified by IHC status. Breast and nodal pCR were compared, and multivariable models tested independent predictors.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/immunohistochemical-status-predicts-pathologic-complete-response-to-neoadjuvant-therapy-in-her2-overexpressing-breast-cancers/342281/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/immunohistochemical-status-predicts-pathologic-complete-response-to-neoadjuvant-therapy-in-her2-overexpressing-breast-cancers/342281.png","ImageObject",300,407,{"name":92,"@type":93},"Aurelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How is HER2 status defined in this study?","Question",{"text":112,"@type":113},"HER2+ is defined by IHC and ISH, where HER2 overexpression corresponds to IHC3+ or IHC2+/ISH+.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What was the main outcome analyzed regarding treatment response?",{"text":117,"@type":113},"The study analyzed pathologic complete response (pCR) at both the breast and nodal levels.",{"name":119,"@type":110,"acceptedAnswer":120},"What does the study conclude about the predictive value of IHC status?",{"text":121,"@type":113},"IHC status predicts pCR and may help select patients with HER2+ breast cancer who benefit most from neoadjuvant therapy.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},342281,1790519308,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099514068365,"https://ap-avatar.wpscdn.com/avatar/10000253d8d9f28188e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1794309523707217728","Ann Surg Oncol (2025) 32:931–943  \n[https://doi.org/10.1245/s10434-024-16470-8](https://doi.org/10.1245/s10434-024-16470-8)  \nORIGINAL ARTICLE – BREAST ONCOLOGY  \nImmunohistochemical Status Predicts Pathologic Complete Response to Neoadjuvant Therapy in HER2‑Overexpressing Breast Cancers  \nLeah Winer, MD1, Karen J. Ruth, MS2, Richard J. Bleicher, MD3, Rajeswari Nagarathinam, MD4, Melissa McShane, MD5, Andrea S. Porpiglia, MD1, Mary T. Pronovost, MD3, Allison Aggon, DO3, and  \nAustin D. Williams, MD, MSEd3  \n1Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA; 2Biostatistics Facility, Fox Chase Cancer Center, Philadelphia, PA; 3Division of Breast Surgical Oncology, Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA; 4Department of Pathology, Fox Chase Cancer Center, Philadelphia, PA; 5Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA  \nABSTRACT  \nBackground. Human epidermal growth factor receptor 2 (HER2) overexpression (HER2+) is defined by immunohistochemistry (IHC) and in situ hybridization (ISH) as IHC3+ or IHC2+/ISH+ . Response differences to neoadjuvant anti-HER2 therapy (NT) in IHC3+ versus IHC2+/ ISH+ breast cancer patients are poorly characterized. We explored whether pathologic complete response (pCR) varies by HER2 IHC status.  \nMethods. Patients with stage I–III HER2+ breast cancer undergoing NT and surgery between 2013 and 2020 were identified from the National Cancer Database and stratified by IHC status. Breast and nodal pCR were analyzed. Results. Of 40,711 HER2+ patients, 83% were IHC3+ and 17% were IHC2+/ISH+ . IHC3+ patients were more likely to be hormone receptor (HR)-negative (33 vs. 21%), have cT3/4 tumors (24 vs. 21%), and be cN+ (52 vs. 47%; all p \u003C 0.0001) . Breast conservation rates were similar (each 43%, p = 0.32), although IHC3+ axillary lymph  \nThis paper was presented as an ePoster at the 2024 Society of Surgical Oncology Annual Meeting in Atlanta, GA, USA, and is being submitted as an original article. It is not under consideration at any other journal.  \n© The Author(s) 2024  \nFirst Received: 5 August 2024  \nAccepted: 23 October 2024  \nPublished online: 9 November 2024  \nA. D. Williams, MD, MSEd  \n[e-mail: Austin.Williams@fccc.edu](e-mail: Austin.Williams@fccc.edu)  \nnode dissection rates were lower (41 vs. 45%, p \u003C 0.0001) . Among all patients, breast pCR was 49%, while nodal pCR was 64% . Compared with IHC2+/ISH+, IHC3+ had higher unadjusted breast (54 vs. 22%, p\u003C 0.0001) and nodal (69 vs. 37%, p \u003C 0.0001) pCR rates. When stratified by HR status, pCR was lower for HR+ disease but remained higher among IHC3+ patients. Analysis of T1cN0 primaries mirrored these trends. In multivariable analysis, IHC3+ remained an independent predictor of breast (odds ratio [OR] 3.91, confidence interval [CI] 3.65–4.19, p \u003C 0.0001) and nodal (OR 3.40, CI 3.12–3.71, p \u003C 0.0001) pCR.  \nConclusion. HER2 IHC status predicts pCR and may help select breast cancer patients who derive the greatest benefit from NT. These findings provide further evidence that revision of HER2 classification may improve clinical management.  \nKeywords Breast cancer · Human epidermal growth factor (HER2) · Immunohistochemistry (IHC) · In situ hybridization (ISH) · Pathologic complete response (pCR)  \nHuman epidermal growth factor receptor 2 (HER2) is a membrane tyrosine kinase receptor overexpressed in approximately 15% of invasive breast cancers.1 According to the National Comprehensive Cancer Network (NCCN) clinical oncology guidelines, all patients with newly diagnosed invasive breast cancer should undergo HER2 testing with immunohistochemistry (IHC) to evaluate protein expression levels.2 For those with equivocal results (IHC2+), reflex in situ hybridization (ISH) is required to quantify HER2  \ngene expression. By convention, HER2 overexpression (HER2+) is defined as either IHC3+ or IHC2+/ISH+, with previous studies demonstrating high concordance between IHC expr","cbCaib8Zy4ZwKRK5","https://ap.wps.com/l/cbCaib8Zy4ZwKRK5","pdf",564191,13,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Keywords","[{\"question\":\"How is HER2 status defined in this study?\",\"answer\":\"HER2+ is defined by IHC and ISH, where HER2 overexpression corresponds to IHC3+ or IHC2+/ISH+.\"},{\"question\":\"What was the main outcome analyzed regarding treatment response?\",\"answer\":\"The study analyzed pathologic complete response (pCR) at both the breast and nodal levels.\"},{\"question\":\"What does the study conclude about the predictive value of IHC status?\",\"answer\":\"IHC status predicts pCR and may help select patients with HER2+ breast cancer who benefit most from neoadjuvant therapy.\"}]","Immunohistochemical Status Predicts Pathologic Complete Response to Neoadjuvant Therapy in HER2-Overexpressing Breast Cancers | PDF",1790046002,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/48bb8b09a721cfadc1967d2f8fd304ef.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8569ef44de2302e8784204cb7947b89b.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2af562dc575ac68f07af8dc24f89c790.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cf3bf1a0008090b2c600f9204c00b4d8.webp",980,1301]